GOSS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Gossamer Bio Inc (GOSS) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock has experienced significant negative catalysts, including failed clinical trials, multiple analyst downgrades, legal investigations, and a bearish technical outlook. Additionally, the company's financials, while showing some YoY improvements, remain negative overall. The lack of positive trading signals and the absence of recent congressional trading data further reinforce the recommendation to avoid investing in this stock at this time.
The technical indicators for GOSS are overwhelmingly bearish. The MACD histogram is negative and expanding, RSI is at 6.178 indicating extreme oversold conditions, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading well below key support levels, with S1 at 0.609 and S2 at 0.0979, and the current price of 0.401 suggests further downside potential.
The company's revenue increased by 40.23% YoY in Q3 2025, and net income improved by 56.55% YoY, showing some operational progress.
Phase 3 PROSERA trial failure, leading to an 80% stock price drop.
Multiple analyst downgrades with price targets significantly reduced (e.g., Barclays to $0.30 from $9).
Legal investigations into potential securities fraud.
Hedge funds significantly increasing their selling activity (535.94% increase).
Regulatory uncertainty and debt restructuring challenges.
In Q3 2025, revenue increased to $13.29M (up 40.23% YoY), net income improved to -$48.22M (up 56.55% YoY), and EPS increased to -0.21 (up 50% YoY). However, the company remains unprofitable with significant losses.
Analysts have downgraded the stock across the board, citing disappointing trial results, regulatory uncertainty, and financial challenges. Price targets have been drastically reduced, with the highest at $1 and the lowest at $0.30.
